CD8A and myeloid sarcoma: Their superior ability to be recognized by both CD4+ and CD8+ T cell responses should be harnessed to induce both systemic and tissue resident T cell memory to protect from symptomatic acute EBV infection, namely infectious mononucleosis, and the associated risk for EBV positive malignancies and the autoimmune disease multiple sclerosis (MS) (Ruhl et al., 2020).